Clinical trials: Geriatric Disorders
Meningococcal Disease, Meningococcal Meningitis
Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years
The primary objective of this study is to demonstrate the equivalence of rMenB+OMV NZ lot 1 to rMenB+OMV NZ lot 2 when administered to adolescents, as measured by human serum bactericidal activity (hSBA) geometric mean titers…
- Trial name
- NCT01423084
- Testing
- Serogroup B meningococcal vaccine
- Where
- 13 sites in Australia, Canada
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Novartis
Depressive Disorder
GSK372475 PK Study in Healthy Volunteers
This study will consist of 4 parallel cohorts of healthy volunteers (elderly male, elderly female, young male and young female). Subjects will receive either GSK372475 1.5mg or placebo for 28 days.
- Trial name
- NCT00728208
- Testing
- GSK372475
- Where
- Germany
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Tract Infections, Wheezing Lower Respiratory Illness
OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness
This study will assess the efficacy and safety of OM-85 compared to placebo in reducing the number of respiratory tract infections (RTIs) in children aged between 6 months and 5 years.
- Trial name
- NCT05677763
- Testing
- OM-85
- Where
- 42 sites in Germany, Hungary and 4 more
- Volunteers
- 525 people
- Sponsor
- OM Pharma SA
Influenza
A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants
Current influenza vaccines have a reduced efficacy in the elderly. This study will investigate the immunogenicity, safety and tolerability of an adjuvanted influenza vaccine in elderly participants.
- Trial name
- NCT00479648
- Testing
- CSL412, Inactivated trivalent influenza vaccine
- Where
- United Kingdom
- Volunteers
- 612 people, healthy volunteers welcome
- Sponsor
- Seqirus
Precursor Cell Lymphoblastic Leukemia-lymphoma
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), safety and toxicity, and pharmacokinetics (PK) of ixazomib administered intravenously in combination with…
- Trial name
- NCT03888534
- Testing
- Ixazomib
- Where
- 7 sites in United States, Spain
- Sponsor
- Millennium Pharmaceuticals, Inc.
Rabies (Healthy Volunteers)
Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen
To demonstrate the immunogenicity of Sinovac rabies vaccine is non-inferior to the active-controlled rabies vaccine (Verorab®) after post-exposure prophylaxis (PEP) vaccination, and to confirm its satisfying safety profile in the…
- Trial name
- NCT07055893
- Testing
- Rabies vaccine, Verorab®
- Where
- Pakistan
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Hypertension
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension
This 14 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients 65 years of age or older with high blood pressure.
- Trial name
- NCT00412932
- Testing
- Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide
- Where
- 29 sites in United States
- Volunteers
- 178 people
- Sponsor
- Daiichi Sankyo
Gastroesophageal Reflux
Study Evaluating Pantoprazole in Adolescents With GERD
The purpose of this study is characterize the PK profile of single and multiple doses of pantoprazole in adolescents aged 12 to 16 years with Gastroesophageal Reflux Disease (GERD).
- Trial name
- NCT00367614
- Testing
- pantoprazole
- Volunteers
- 20 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Generalized Anxiety Disorder
6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
This is an open-label, multi-site, 6-month study of an investigational compound in elderly outpatients, age 65 years old or above, to assess the long-term safety and tolerability of the compound in the treatment of elderly…
- Trial name
- NCT00738738
- Testing
- PD-0332334
- Where
- 2 sites in United States
- Sponsor
- Pfizer
SARS-CoV-2
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04470427
- Testing
- mRNA-1273
- Where
- 100 sites in United States
- Volunteers
- 30,415 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cystic Fibrosis
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR)…
- Trial name
- ENVISION (NCT00909727)
- Testing
- Ivacaftor
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 52 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Glycogen Storage Disease Type II Infantile Onset
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and ERT-naïve pediatric subjects with IOPD.
- Trial name
- ROSSELLA (NCT04808505)
- Testing
- Cipaglucosidase alfa, Miglustat
- Where
- 14 sites in United States, Germany and 4 more
- Volunteers
- 36 people
- Sponsor
- Amicus Therapeutics
Herpes Zoster
Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)
PRIMARY OBJECTIVES Two co-primary objectives are: To demonstrate that the immunogenicity of ZOSTAVAX administered by intramuscular route (IM) is non-inferior to ZOSTAVAX administered by subcutaneous route (SC) To demonstrate that…
- Trial name
- NCT01391546
- Testing
- ZOSTAVAX
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Renal Insufficiency
Study to Assess Bemiparin Pharmacokinetics in Renal Insufficiency and in the Elderly
Open pharmacokinetic study with 5 parallel groups and two treatment phases (bemiparin 3,500 IU multiple dose and bemiparin 115 IU/kg single dose).
- Trial name
- NCT00413088
- Testing
- bemiparin
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
Atrophy, Muscular
A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days
The primary objective is to determine the pharmacokinetics, safety and tolerability of SRT2104 in healthy elderly subjects following single and 28 days dosing. The secondary objectives of the study are: 1.
- Trial name
- NCT00964340
- Testing
- SRT2104
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older
The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of Fluviral™ containing the influenza strains recommended for the 2013-2014 season in adults aged 18 years and older.
- Trial name
- NCT01878825
- Testing
- Fluviral™
- Where
- Canada
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease, Dementia
Nutritional Programme for Dementia Elderly Patient
The main objective of this study is the improvement of the quality of life and state of health of elderly people with cognitive deterioration and their families through a weight loss prevention programme.
- Trial name
- NCT00479843
- Testing
- Nutritional programme
- Where
- Spain
- Volunteers
- 946 people
- Sponsor
- Société des Produits Nestlé (SPN)
Respiratory Disorders
A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.
The purpose of this study is to test if the vaccine is working well in COPD patients aged 40 to 80 years old to reduce episodes of worsening symptoms ("exacerbations") and to gather further information on safety and immune…
- Trial name
- NCT03281876
- Testing
- NTHi Mcat investigational vaccine (GSK3277511A)
- Where
- 67 sites in United States, Belgium and 6 more
- Volunteers
- 606 people
- Sponsor
- GlaxoSmithKline
Influenza, Orthomyxovirus Infection
Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
This is a multi-center study designed to evaluate the safety and immunogenicity of a Fluzone revaccination in elderly adults aged ≥ 65 years. Primary Objective: To describe the safety profile for all subjects.
- Conditions
- Influenza, Orthomyxovirus Infection, Myxovirus Infection
- Trial name
- NCT00775450
- Testing
- Influenza Virus Vaccine USP Trivalent Types A and B
- Where
- 28 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumonia, Pneumococcal
Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.
- Trial name
- NCT04278248
- Testing
- 23-Valent Pneumococcal Polysaccharide Vaccine
- Where
- China
- Volunteers
- 1,940 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.